CYT
Price:
$3.02
Market Cap:
$108.71M
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.[Read more]
Industry
Biotechnology
IPO Date
2021-06-18
Stock Exchange
NASDAQ
Ticker
CYT
According to Cyteir Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -3.25. This represents a change of -2.93% compared to the average of -3.35 of the last 4 quarters.
The mean historical PE Ratio of Cyteir Therapeutics, Inc. over the last ten years is -12.27. The current -3.25 PE Ratio has changed 2.55% with respect to the historical average. Over the past ten years (40 quarters), CYT's PE Ratio was at its highest in in the June 2021 quarter at -1.11. The PE Ratio was at its lowest in in the June 2020 quarter at -23.10.
Average
-12.27
Median
-12.64
Minimum
-22.48
Maximum
-1.32
Discovering the peaks and valleys of Cyteir Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual PE Ratio = -1.32
Minimum Annual Increase = -75.13%
Minimum Annual PE Ratio = -22.48
Year | PE Ratio | Change |
---|---|---|
2022 | -1.32 | -75.13% |
2021 | -5.32 | -73.33% |
2020 | -19.96 | -11.18% |
The current PE Ratio of Cyteir Therapeutics, Inc. (CYT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-8.87
5-year avg
-12.27
10-year avg
-12.27
Cyteir Therapeutics, Inc.’s PE Ratio is less than Nuvation Bio Inc. (-1.39), less than Magenta Therapeutics, Inc. (-0.15), greater than Neoleukin Therapeutics, Inc. (-5.86), less than Graphite Bio, Inc. (-0.13), greater than Foghorn Therapeutics Inc. (-3.46), less than C4 Therapeutics, Inc. (-2.49), less than Prelude Therapeutics Incorporated (-0.67), greater than Rezolute, Inc. (-4.39), less than Molecular Partners AG (-2.46), less than MediciNova, Inc. (-0.04), greater than Anebulo Pharmaceuticals, Inc. (-4.96), greater than Champions Oncology, Inc. (-183.74), less than Eliem Therapeutics, Inc. (0), less than HCW Biologics Inc. (-0.41), greater than Monte Rosa Therapeutics, Inc. (-4.83), less than Nkarta, Inc. (-1.51), less than Lyell Immunopharma, Inc. (-0.78), less than Generation Bio Co. (-0.49), less than Sana Biotechnology, Inc. (-1.32),
Company | PE Ratio | Market cap |
---|---|---|
-1.39 | $910.41M | |
-0.15 | $42.44M | |
-5.86 | $8.20M | |
-0.13 | $185.19M | |
-3.46 | $280.19M | |
-2.49 | $266.12M | |
-0.67 | $63.04M | |
-4.39 | $252.63M | |
-2.46 | $195.74M | |
-0.04 | $101.53M | |
-4.96 | $39.29M | |
-183.74 | $111.70M | |
0 | $342.68M | |
-0.41 | $15.13M | |
-4.83 | $431.90M | |
-1.51 | $160.19M | |
-0.78 | $181.40M | |
-0.49 | $71.13M | |
-1.32 | $381.79M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cyteir Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Cyteir Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Cyteir Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Cyteir Therapeutics, Inc. (CYT)?
What is the highest PE Ratio for Cyteir Therapeutics, Inc. (CYT)?
What is the 3-year average PE Ratio for Cyteir Therapeutics, Inc. (CYT)?
What is the 5-year average PE Ratio for Cyteir Therapeutics, Inc. (CYT)?
How does the current PE Ratio for Cyteir Therapeutics, Inc. (CYT) compare to its historical average?